GIGA-CARBON-NEUTRALITY
10.12.2021 14:07:08 CET | Business Wire | Press release
Giga Carbon Neutrality (GCN), the clean commercial transportation and technology company, today announced that it has secured a contract to supply 200 hydrogen and battery EV powered heavy trucks and associated engineering machinery from The People’s Government of Ejin Horo Banner, an administrative division of Ordos City of the Inner Mongolia Autonomous Region in China.
The GCN trucks will be produced in a strategic partnership with Xuzhou Construction Machinery Group (XCMG) and Sunrise Power at a new clean energy commercial vehicle production facility in Ordos City, China. XCMG is China’s number one and the world’s number three construction machinery company.
The partners plan to invest Rmb2.3 billion (US$360 million) to establish the new plant, which will produce clean energy commercial vehicles, hydrogen power systems and associated equipment for customers in China and across Asia. Work to build the new plant is expected to be complete in 2023, with the first 200 vehicles scheduled to roll off the production line in the first half of 2022.
In November 2021, GCN announced its intention to launch a full range of 21 battery-electric and hydrogen fuel-cell vehicles by the end of 2023, which will be configurable to a wide range of commercial use cases. The first vehicles are available to order now for delivery in 2022.
Marty Wade, CEO at Giga Carbon Neutrality, comments: “This a milestone deal for GCN and clean energy commercial transportation. We believe it is the amongst the biggest signed with any company for hydrogen and battery EV trucks so far and that it will make GCN the one of the leading providers of hydrogen-powered commercial vehicles worldwide.”
See GCN’s Hydrogen Tractor on the road in China at https://youtu.be/6MWfu8zswTo
About Giga Carbon Neutrality (www.gigacarbonneutrality.com )
Giga Carbon Neutrality is a clean energy trucking and technology company with a supporting ‘Energy-as-a-Service’ (EaaS) offering that makes running clean, reliable vehicle fleets easy for industrial and commercial transportation companies. GCN'S portfolio includes battery-electric and hydrogen fuel cell vehicles, clean energy storage, charging and refueling infrastructure, and specialist financing to support the transition to zero-emission vehicles.
About Sunrise Power Co Ltd (www.fuelcell.co.cn )
Founded in April 2001, Sunrise Power Co., Ltd. is China's first joint-stock enterprise dedicated to industrialization of fuel cells. The company integrates scientific research and development, engineering transformation, product manufacturing and personnel training, and is mainly engaged in design, development, manufacturing and technical service of hydrogen fuel cell membrane electrodes, stack modules, systems and related test equipment. At present, it has a total of 541 patent applications, including 4 international patents, and covering all levels of key materials, key components, stacks and systems of proton exchange membrane fuel cells.
About XCMG (www.xcmg.com )
XCMG is the iconic brand of the equipment industry of China. XCMG group, 78 years of history, is a multinational enterprise giant. No. 1 in Chinese construction machinery industry, top 3 in the industry in the whole world, XCMG has been supplying the products to over 187 countries and regions.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211210005250/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom